These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 17435082)

  • 1. PDUFA reauthorization--drug safety's golden moment of opportunity?
    Hennessy S; Strom BL
    N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082
    [No Abstract]   [Full Text] [Related]  

  • 2. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 4. What ails the FDA?
    Okie S
    N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
    [No Abstract]   [Full Text] [Related]  

  • 5. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

  • 6. User fees and beyond--the FDA Safety and Innovation Act of 2012.
    Kramer DB; Kesselheim AS
    N Engl J Med; 2012 Oct; 367(14):1277-9. PubMed ID: 23034017
    [No Abstract]   [Full Text] [Related]  

  • 7. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
    DerGurahian J
    Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
    [No Abstract]   [Full Text] [Related]  

  • 8. Regulatory watch: impact of PDUFA on regulatory decision-making.
    Hay M
    Nat Rev Drug Discov; 2010 Aug; 9(8):585. PubMed ID: 20671755
    [No Abstract]   [Full Text] [Related]  

  • 9. The Prescription Drug User Fee Act of 1992: speeding up the drug approval process.
    Bierut MB
    Healthspan; 1992 Dec; 9(11):12-4. PubMed ID: 10123552
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Berry MD
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
    [No Abstract]   [Full Text] [Related]  

  • 11. New drug law to speed scientific review.
    Nature; 1992 Oct; 359(6396):563. PubMed ID: 1406977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA proposes higher fees for drug approvals to cover postmarketing surveillance.
    Tanne JH
    BMJ; 2007 Jan; 334(7586):177. PubMed ID: 17255596
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug-review deadlines and safety problems.
    Carpenter D; Zucker EJ; Avorn J
    N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The marketplace can't give us the drug safety data we need.
    Avorn J
    MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA dependence on drug industry.
    Lawson GW
    J Natl Med Assoc; 2005 Jul; 97(7):1039-40. PubMed ID: 16080677
    [No Abstract]   [Full Text] [Related]  

  • 16. Speed, Safety, and Industry Funding - From PDUFA I to PDUFA VI.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2017 Dec; 377(23):2278-2286. PubMed ID: 29211663
    [No Abstract]   [Full Text] [Related]  

  • 17. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 18. User fees to hasten FDA review.
    Gershon D
    Nature; 1992 Oct; 359(6396):567. PubMed ID: 1406982
    [No Abstract]   [Full Text] [Related]  

  • 19. Learning the value of drugs--is rofecoxib a regulatory success story?
    Eisenberg RS
    N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
    [No Abstract]   [Full Text] [Related]  

  • 20. User fees for faster drug reviews. Are they helping or hurting the public health?
    Thompson L
    FDA Consum; 2000; 34(5):25-9. PubMed ID: 11590789
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.